Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.
about
Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with PsoriasisIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesEfficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.Introducing vedolizumab to clinical practice: who, when, and how?Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to InfliximabClinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.Optimizing thiopurine therapy in inflammatory bowel disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Immunomodulators for all patients with inflammatory bowel disease?Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.Therapeutic drug monitoring of biologics for inflammatory bowel disease.Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment responseReview article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Advances in the medical management of paediatric IBD.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseaseSafety considerations when using anti-TNFα therapy to treat Crohn's disease.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.Adalimumab for the treatment of pediatric Crohn's disease.Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era".Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.A dermatologist guide to immunogenicityTherapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
P2860
Q28554923-EC7040C6-443A-4EED-ABD1-AB580E54B26DQ30235581-53832D83-6807-46BC-BBB0-27722B3B8E13Q30995889-1F5EE5F2-0A5E-41F3-9F06-F3FEDB7E4C3BQ33874790-7F96C14F-50B8-4DC5-930A-93C77966B1E3Q34147687-B157A9CF-651A-44BE-99E5-2346AD54ECFDQ34293689-2D5FF2A2-8818-4075-AB02-17DB2D1C254EQ35177220-24DAD087-62FE-4166-BBDD-7438A9D8A090Q35562290-96995E21-15DF-48F7-81CD-ECECBC2E25A2Q35869305-B12427A1-B7F6-4324-854A-EECD82ED12E5Q36819607-3AC35F98-8047-4C09-93A9-0B3E8DF1EE76Q37800458-CA05DB3E-3AEE-4272-AD38-F635A2EC17ACQ37814549-756D12C8-4494-4F75-9E37-131C23DF097AQ37820898-313A25D3-24C0-4071-A19C-C48F71657A0AQ37823320-D3F9D863-F37C-44F2-8523-C62189C42519Q37853354-203BFE12-2A97-4600-82F9-2CFA23FAB5BBQ37918330-BE1E4F57-1AC2-444E-9265-84F77A4F0C19Q37948705-E1B67DE9-CEC7-4A28-A055-0DF959310941Q37996426-C93FA0D5-C513-484E-929E-56A2E5F81C17Q38059422-A961669A-2C7F-4CEC-8388-078BC219A552Q38063585-769C7791-1375-4F35-8DB7-F849A5D1E2D3Q38083093-15F42A60-43D8-4F7C-BCE3-AB058CE00882Q38104578-F5AB84D2-96A0-459C-90CA-CF5AB8EDB6E6Q38118313-FFAEB22A-4013-4AE7-959C-6A8FB87C56F0Q38121115-FEE294FF-EFAF-4F27-85EC-1E8C590B2823Q38130044-A68F4850-F0A4-4FA5-B229-9A9F41811396Q38176154-8DF1468F-12F6-4E83-90C1-D959F9B67E5AQ38191334-4BD3B390-6151-4C97-91E1-1061EDF79B7DQ38206507-1BC82E6B-5FD5-4F10-BF6A-8615CBE1585DQ38268598-EB262444-3BD1-4DE9-866A-430E42FC4D4BQ38315640-8EC117EA-5E38-4AE8-B432-A9BBDDA9FAA6Q38426876-E2A0E0A2-1C39-4C55-AFAB-A2AC9DF73F1AQ38554433-1680AED4-448E-4D25-9FE6-E7A85DABA786Q38628770-0F8682D2-DF1C-4331-A337-F50A98F72E54Q38631012-7626F651-2F42-437F-A0DD-299B967BDC01Q38635824-4F815E1C-A3AD-435F-B712-9C0007D3CA9FQ38822920-138AA921-1357-4309-BA1A-36B40BCDC860Q39278646-03B312C7-F730-4040-B37E-31515AF350A0Q39297511-95DED404-55C8-4CE6-AA2D-836E80ACFD15Q39834984-23C42B2B-BE98-40CA-8AF9-2E0AB46A287AQ41482221-6BAC276E-163B-423A-A75D-B8E71BBF0293
P2860
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence and clinical signifi ...... a critical systematic review.
@en
Incidence and clinical signifi ...... a critical systematic review.
@nl
type
label
Incidence and clinical signifi ...... a critical systematic review.
@en
Incidence and clinical signifi ...... a critical systematic review.
@nl
prefLabel
Incidence and clinical signifi ...... a critical systematic review.
@en
Incidence and clinical signifi ...... a critical systematic review.
@nl
P2860
P356
P1476
Incidence and clinical signifi ...... a critical systematic review.
@en
P2093
Andrea Cassinotti
Simon Travis
P2860
P304
P356
10.1002/IBD.20899
P577
2009-08-01T00:00:00Z